Announcing the opening of our new state of the art GMP manufacturing facility, built with cell therapies in mind! It's entirely animal-free and has large-scale bioreactors with room for expansion, backed by experienced manufacturing, quality, and regulatory teams. Our first cytokine to roll off the line is GMP Human IL-7.
Bio-Techne and Carterra have initiated a clinical research collaboration for COVID-19 variant analysis. We are bringing together cutting-edge technologies and expertise to advance the world's understanding of COVID-19 variants' mechanism of action.
Learn from industry experts in our new eBook: iPSCs From the Bench to the Clinic. Explore QC guidelines for clinical-grade iPSC lines and raw material qualification for stem cell therapy manufacturing. Written in collaboration with RegMedNet.
Genome Engineering Services for Cell Therapy Manufacturing. This brochure describes the benefits of using TcBuster, our non-viral gene transfer system and our range of services for GMP cell engineering.
New User Guide: GMP ProDots™ Proteins. Our guide shows how the ProDots formulation enables closed processing addition of cytokines to culture media and reduces the risk for cell therapy manufacturing.
The new Simple Plex AAV2 assay provides fast and efficient viral quantitation with superior specificity. View AAV Titer Assay
Bio-Techne and Catamaran Bio announce expanded collaboration for CAR-NK cell manufacturing technologies. Learn More About Catamaran
Bio-Techne announces a partnership with Autolomous to enhance its GMP Gene Engineering and Cell & Gene Therapy manufacturing capabilities with the AutoloMATE™ electronic batch record system. Learn More About Autolomous
Bio-Techne has joined the Cell and Gene Therapy Catapult consortium of researchers and companies to advance process analytical technology (PAT) for CGT development. Learn More About Catapult
New Application Note! Assess the purity of your cell therapy product with Micro-Flow Imaging: Detection of Cloudz cell activation microspheres in natural killer cell therapeutics. Download Application Note
New eBook! Next-generation analytical solutions for Cell & Gene Therapy. Download eBook
Bio-Techne announces commercial release of Abby automated Western system for Simple Western and introduces Stellar Modules for Jess. Learn More About Abby
Bio-Techne completes acquisition of Asuragen, Inc. for best-in-class molecular diagnostic and research products, GMP manufacturing facility, and CLIA-certified laboratory. Learn More About Asuragen
Tocris, a Bio-Techne brand, releases Ancillary Material Grade Compounds, an intermediate grade designed to streamline the transition from research use only (RUO) small molecules to GMP-grade. Learn More About Small Molecules
Bio-Techne announces launch of Cultrex™ UltiMatrix BME to support organoid and pluripotent stem cell cultures. Learn More About Cultrex UltiMatrix
Bio-Techne announces ISO 9001-2015 certification for its GMP manufacturing facility in Bristol, UK. Read About New Certification
Bio-Techne and Luminary Therapeutics sign license agreement for use of Bio-Techne's TcBuster™ for the development of Luminary's CAR-T cell therapies. Visit our Gene Engineering page to learn more about TcBuster from our Genome Engineering Services Team. View Our Gene Engineering Page
Raw Materials at Scale – Success Factors for Commercial Cell and Gene Therapy Manufacturing. An eBook written in collaboration with Phacilitate exploring the best practices for scaling out cell and gene therapy manufacturing. Read Our eBook Here
ScaleReady, a joint venture between Bio-Techne, Fresenius Kabi, and Wilson Wolf, brings together proven tools and technologies for cell culture, cell activation, gene editing, and cell processing from its founding partners. Learn More About Our Partnership
Bio-Techne announces strategic investment in Eminence. Eminence will use the financing proceeds to expand its manufacturing capacity and increase the service capabilities of its China-headquartered GMP media production facility. Read About Eminence GMP Media Facility
Regulus Therapeutics Collaborates with Bio-Techne for Biomarker Development. Regulus has utilized two Bio-Techne branded product lines, ProteinSimple and Exosome Diagnostics, to aid in their clinical trial patient testing. Learn More About Our Collaboration
Bio-Techne Announces ISO 13485:2016 Certification for the Woburn, MA Manufacturing Facility. The Woburn facility produces Cloudz™ Cell Activation Kits, a magnetic-free microsphere technology for the robust and reliable expansion of immune cells, including T cells and NK cells, representing a pivotal component of the cell and gene therapy workflow. Learn More About Our Manufacturing Certification
Bio-Techne Announces Grand Opening of our new, state-of-the-art GMP Manufacturing Facility in Saint Paul Minnesota. Learn About Our GMP Facility
B-MoGen Biotechnologies officially becomes part of R&D Systems. B-MoGen, a genome engineering services company, was acquired by Bio-Techne in 2019. Read About Our Gene Engineering Services
GMP ProDots™ Proteins are now available. These GMP cytokines are formulated as dissolvable spheres enclosed inside sterile, weldable bags for closed processing cytokine addition. View ProDots at R&D Systems
Webinars and Presentations
Learn about "Scalable and Customizable Solutions for Cell and Gene Therapy Manufacturing" from Bio-Techne’s Nithya Jesuraj, PhD who is presenting at Cell & Gene Therapy Manufacturing & Commercialization on September 21.
Join our upcoming webinar “Latest Tools for 3D Cell Culture & Organoids” hosted by Bio-Techne's Yas Heidari, Ph.D. This webinar will cover how these tools can overcome common 3D and organoid culture challenges.
Join our on-demand webinar “Fitting Product to Process – Raw Materials Customization for Cell Therapy Manufacturing Success”. This webinar discusses customization case studies and how to identify the right suppliers for your process.
Join our on-demand webinar with two parts. The first talk addresses optimizing research and GMP ex vivo stem cell models, and the second talk presents Bio-Techne’s workflow solutions for immunotherapy manufacturing processes.
Bio-Techne is hosting our next Cell and Gene Therapy Virtual Symposium. At our last event, we discussed “The Challenges of Analyzing ATMPs” and our speakers shared solutions to overcome these challenges. To create therapies that are accessible to all, it is key that manufacturing can be completed in a scalable and cost-effective manner. So, this time we shall be exploring the challenges and discussing possible solutions for streamlining the manufacturing process. Join us and be part of the discussion on how we can streamline, scale-up and scale-out!
Bringing a cell or gene therapy from discovery to the clinic cannot be done in isolation. Join Dr. Derek Hei from BlueRock Therapeutics and Dr. Dan Fowler from Rapa Therapeutics as they discuss how their partnerships with Bio-Techne are helping them build robust and scalable manufacturing platforms and facilitate their IND submissions.
Join our panel of industry leading CGT experts as they discuss planning for the successful development of new cell therapies using new raw materials and technologies. Topics include raw material optimization, best practices, risk assessment and challenges for new raw material, regulatory considerations, scale up and production, and more.
Listen to a discussion by our panel of experts, Jean Stanton (J&J), John Tomtishen (Novartis), Dr. Sadik Kassim (Mustang Bio), and Dr. Diane Wotta (Bio-Techne), around what GMP really means in the context of raw materials and ancillary reagents; the quality of raw materials required along the commercialization pathway; when to start using GMP materials; and the current regulatory landscape.
Cell and gene therapy is a rapidly advancing field that holds a lot of promise for treating a wide range of diseases. In this webinar we'll discuss how our Maurice and MFI 5200 systems can assist with the cell and gene therapy workflow.
Cell Analysis and Host Response
Bio-Techne looks forward to welcoming you to this exciting virtual event to discuss the latest topics within the cell & gene therapy community. The theme for this 2nd virtual symposium is a discussion around the “Challenges of analyzing ATMPs”. Join us to find out from leading scientists how they are pushing the boundaries of cell & gene therapy research.
Monitoring immune responses accurately is critical. From acute infections to cancer immunotherapy, the identity and level of secreted cytokines is needed to understand and control the immune system. This webinar will describe the assays used and the importance of obtaining accurate results.
Innovative Capillary Electrophoresis Techniques for Gene Therapy R&D at ProteinSimple
Learn how various capillary electrophoresis techniques can be easily implemented along the development path to support gene therapy development.
The Next Generation of AAV Characterization Tools by ProteinSimple
In this webinar, join Tony Bou Kheir, PhD, from the Cell and Gene Therapy Catapult in London, as he showcases the Cell and Gene Therapy Catapult’s adeno-associated viruses (AAV) analytical platform and advantages it offers to current industry standards.
Bio-Techne looks forward to welcoming you to this exciting virtual symposium event to discuss the latest topics within the Cell & Gene Therapy community. This event aims to keep everyone connected, communicating and collaborating to advance the cell and gene therapy research and beyond from discovery to clinic.
Gene therapy holds promise for treating a wide range of diseases by precisely altering the genetic composition of cells. Join John Lougheny, director of VAR&D at Merck & Co. Inc. and Chris Heger from ProteinSimple as they demonstrate how the Maurice platform can be used to measure surface charge of an LNP-based mRNA vaccine, and how to assess purity, stability and concentration of AAVs.
Bio-Techne is proud to partner with the London Stem Cell Network (LSCN) to present our first Stem Cell and Organoid Virtual Workshop. Watch on-demand now to learn more from leading experts on the advances in stem cells and organoids, including a panel discussion looking to the future of induced pluripotent stem cell (iPSC) therapies.
Organoid and 3-D cell culture are emerging as pivotal systems for understanding human organ development, modeling disease, screening for drug efficacy or toxicity, and investigating personalized medicine. The reagents and protocols needed to culture these advanced multi-cellular in vitro tissues vary by organ, species, and whether they are being generated from tissue or pluripotent stem cells. Watch on demand to find out direct from leading scientists how they are utilizing organoids within their research.
Using iPSC-derived neurons and iPSC-derived cardiomyocytes as examples, this webinar discusses tools to help researchers manage iPSC variability, optimize cell differentiation, monitor and characterize differentiation efficiency, and translate their protocols towards clinical application.
Induced pluripotent stem cells are a potential source for developing autologous cell therapies. Here we provide a streamlined regulatory (cell manufacturing and preclinical) path towards filing an Investigational New Drug (IND) application to conduct a phase I clinical trial using autologous iPSCs.